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Summary
Chemical synthesis in combination with precision
polymer modification allows the systematic explora-
tion of the effect of protein properties, such as charge
and hydrodynamic radius, on potency using defined,
homogeneous conjugates. A series of polymer-modi-
fied synthetic erythropoiesis proteins were constructed
that had a polypeptide chain similar to the amino acid
sequence of human erythropoietin but differed signif-
icantly in the number and type of attached polymers.
The analogs differed in charge from +5 to −26 at neut-
ral pH and varied in molecular weight from 30 to 54
kDa. All were active in an in vitro cell proliferation
assay. However, in vivo potency was found to be
strongly dependent on overall charge and size. The
trends observed in this study may serve as starting*Correspondence: gkochendoerfer@gryphonrx.com
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60637.points for the construction of more potent synthetic
EPO analogs in the future.
Introduction
Chemical protein synthesis enables the generation of
proteins with novel properties [1–4]. The approach is
based on the chemoselective ligation of unprotected
peptides in aqueous solution. Among the different pep-
tide ligation methods available [5–11], the amide-form-
ing native chemical ligation technique of Dawson et al
[6] is the most extensively proven in practical use.
Although the utility of chemical protein synthesis for
studying protein structure-function relationships has
been considerable, it has only recently been applied to
investigate the therapeutic properties of proteins [1, 4,
12, 13]. For example, synthetic analogs of the chemo-
kine CCL5 (RANTES) have been constructed to contain
nongenetically encoded modifications in the pharma-
cophore regions, yielding compounds several orders of
magnitude more potent at blocking CCR5-mediated
HIV infection than any biologically produced counter-
part [13].
We envisioned that beyond changes in the pharmaco-
phore regions, chemical protein synthesis techniques
might find use in probing and solving other frequently en-
countered problems with protein therapeutics, one of
which is poor circulating half-life. Our strategy was to
produce homogeneous protein conjugates with a con-
stant number of site-specifically attached polymers and
to systematically study the effects of varying charge and
hydrodynamic radius while keeping the protein back-
bone and the polymer attachment sites constant. The
goal was to determine the dependence of therapeutic
properties such as specific activity, circulation lifetime,
and immunogenicity on these variables.
Here, we report the design, construction, and biologi-
cal properties of a series of totally synthetic cytokines
designated “synthetic erythropoiesis proteins” (SEPs),
which exemplify the utility of this strategy. The peptide
backbone of SEP is similar to the sequence of human
erythropoietin (EPO), a natural 166 amino acid glyco-
protein hormone that regulates the proliferation, differ-
entiation, and maturation of erythroid cells [14].
We previously published a report describing the syn-
thesis and properties of the most potent SEP molecule,
SEP-B51 (8−) [12]. In this report, we present the strat-
egy by which this most potent compound was iden-
tified, present additional biological characterization of
this most potent molecule to date, and discuss how the
findings could be applied to produce even more potent
SEP analogs.
Results
Design
A total of four different SEP analogs are described in
this report. A schematic of the polypeptide backbone
and the structures of the polymers attached in the vari-
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372Figure 1. Protein Backbone of SEP and Structure of All Four Different Precision Polymers Employed in This Studyous SEP analogs is shown in Figure 1. Each of these a
aanalogs consisted of an identical polypeptide back-
bone and two distinct precision polymer entities. The w
vanalogs were coded to indicate the protein name (SEP),
the nature of the polymer (L for linear, B for branched), c
aand the molecular weight of the construct. Finally, the
number in parentheses indicates the total charge im- t
tparted on the protein by attachment of two copies of
each respective polymer. s
tThe polypeptide backbone of the four SEP analogs
was designed to be similar to the backbone of EPO [14] A
but to possess seven distinct differences in covalent
structure. First, the glutamate residues at positions 89 g
aand 117 of EPO were mutated to pseudo-homogluta-
mate (see below) to facilitate native chemical ligation. n
tSecondly, all native glycosylation sites of EPO were
eliminated. Wild-type EPO has three N-linked glycosy- b
tlation sites in positions Asn24, Asn38, and Asn83, which
carry predominantly tetrantennary, branched sugars, as t
twell as an O-linked glycosylation site at position Ser126,
contributing an average sugar mass of 12 kDa per EPO
tmonomer. These sites were converted to either lysine
residues (amino acid residues Asn38 and Asn83) or d
pN-levulinyl lysine (amino acid residues Asn24 and
Ser126), respectively. The N-levulinyl moieties at posi- w
mtions 24 and 126 were incorporated to provide an ox-
ime-forming chemoselective attachment site for a poly- 3
cmer bearing an aminooxyacetyl group in SEP-B50 (0)nd SEP-B51 (8−) [7, 15, 16]. For analogs SEP-L30 (0)
nd SEP-B54 (32−), N-levulinyl lysine was replaced
ith N-aminooxyacetyl lysine in order to attach a pyru-
ic-acid-bearing polymer [17]. These two sites were
hosen among the EPO glycosylation sites for polymer
ttachment since they are located on opposite faces of
he protein, and we speculated that site-specific at-
achment of a synthetic polymer exclusively to these
ites might not interfere with protein function. Finally,
he C-terminal amino acid for all SEP constructs was
rg166, which is absent from mature human EPO [18].
The precision polymer moieties were designed to
ive each SEP molecule a large hydrodynamic radius
nd an altered clearance profile, as well as a specific
et charge at physiological pH. We also speculated that
he precision polymers might enhance protein stability
y shielding the folded polypeptide from attack by pro-
eolytic enzymes and might reduce immunogenicity of
he protein backbone, while retaining full biological po-
ency.
The repeat unit of the precision polymer employed in
his study was succinic acid-(4,7,10)-trioxa-1,13-tri-
ecanediamine (see Figure 1). SEP-L30 (0) carried two
olymers consisting of 18 repeat units of this polymer
ith a neutral terminal amide group, resulting in a total
olecular weight (peptide backbone plus polymer) of
0 kDa and no additional charges. All other analogs
arried a branched polymer that consists of (a) a che-
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373moselective linker, (b) a hydrophilic spacer consisting
of one polymer repeat unit, (c) a core structure having
four branching points, (d) a linear polymer having 12
repeat units attached to each branch point, and (e) a
charge control unit at the end of each branch. Each
branched polymer contributed w16 kDa to the total
molecular weight of each analog. In SEP-B50 (0), each
branch carries a neutral amide group, resulting in no
additional charges. The SEP-B51 (8−) polymer carried
an Nα-attached alanyl end group in each branch, result-
ing in one negative charge per branch or a total of eight
negative charges at physiological pH for the two at-
tached polymers. In SEP-B54 (32−), each branch car-
ried a branching core of three Nα-attached glutamyl
residues, resulting in four negative charges per branch
or a total of 32 negative charges at physiological pH for
the two attached polymers.
Chemical Protein Synthesis
Unprotected peptide segments were prepared by opti-
mized in situ neutralization stepwise solid-phase pep-
tide synthesis [19], and linear precision polymers were
assembled by solid-phase assisted polymer synthesis
[20]. The branched precision polymers were assembled
by solution coupling of individual linear precision poly-
mers to a branching template as described in Experi-
mental Procedures. The sequence of the chemical liga-
tion, modification, and deprotection steps to construct
the full-length proteins for SEP-B50 (0) and SEP-B51
(8−) is summarized in Figure 2. This figure also outlines
the protecting group strategy employed in the synthe-
sis. In general, each SEP analog was assembled by li-
gating four separate peptide segments [peptide seg-
ments X modified with precision polymer are denoted
SEP-X-(PP)]: SEP-A-(PP), SEP-B, SEP-C, and SEP-
D-(PP).
Initially, the precision polymer was linked to the desired
peptide segments SEP-A and SEP-D by oxime-forming
ligation [7]. For analogs SEP-B50 (0) and analogs SEP-
B51 (8−), oxime formation was performed between an
aminooxy group on the precision polymer construct
and a levulinic acid moiety on the peptides. Using this
approach, a significant amount of a peptidic side pro-
duct with a mass loss −18 relative to the starting pep-
tide was found after HF cleavage. In addition, a signifi-
cant population of this impure peptide was found after
the oximation reaction in the unreacted peptide pool.
After isolation, it was determined that the side product
is not reactive with any aminooxy compounds and
therefore most likely results from an intramolecular re-
action of the ketone group with a peptide side-chain
functionality. However, this side product was not due
to the formation of an intramolecular thiazolidine bond
between the ketone group and the N-terminal cysteine
residue, since it was present to an even larger extent
in segment SEP-A, which is devoid of an N-terminal
cysteine residue. In addition, this reaction was not re-
versible after treatment with 1 M methoxylamine, which
rapidly cleaves the thiazolidine ring [21, 22]. In order to
overcome this problem, analog SEP-L30 (0) and SEP-
B54 (32−) explored an alternative oxime bond formed
by a pyruvic acid group on the precision polymer and
an aminooxy group on the peptides to generate thepeptides SEP-A-(PP) and SEP-D-(PP). We found that
the starting peptide segments SEP-A and SEP-D could
be produced using optimized in situ neutralization Boc
chemistry with a much higher yield (>2×) when modified
with an aminooxy group compared to the free ketone
group. In addition, use of the aminooxy group on the
peptide allowed for the use of pyruvic acid as a ketone-
bearing moiety on the polymer. Even though levulinic-
acid-based oxime bonds were found to be stable at 4°C
in neutral buffers for several weeks, they were found to
hydrolyze significantly at lower pH and elevated tem-
peratures. In contrast, the pyruvic acid ketone was
>99% stable at 4°C in acetate buffer (pH 4) for 6 months
and for at least 2 weeks in the same buffer at 37°C.
Interestingly, whereas the formation of the levulinic ox-
ime bond was fully reversible in the presence of 1 M
aminooxyacetic acid, as demonstrated in the synthesis
of SEP-B54 (32−), pyruvic acid oximes were completely
stable in the presence of this strong nucleophile, pre-
sumably due to the conjugated nature of the resultant
oxime.
After polymer attachment, the four peptide segments
were ligated by three sequential native chemical li-
gations [6]. After each ligation step, the desired product
was separated from the reactants by reversed-phase
HPLC and characterized by ESI-MS. In the first ligation
step, segment SEP-C was ligated to segment SEP-D-
(PP). After removal of the Acm protecting group on the
N-terminal cysteine on the resulting product SEP-C-D-
(PP), SEP-B was ligated to SEP-C-D-(PP). Following the
first two ligation steps, the cysteine residues at posi-
tions 89 and 117 were alkylated with bromoacetic acid
to form noncoded amino acid residues with carboxylate
side chains (named pseudo-homoglutamate). The ob-
jective of this reaction was to block free thiol groups
that may interfere with the folding and stability of the
full-length protein, without affecting its function. Cys
161 was protected with a picolinyl group [23], and
Cys33 was protected by an Acm group, and thus both
residues were not modified during this transformation.
After deprotection of Cys 161 and removal of the Acm
group on the N-terminal cysteine, SEP-A(PP) was li-
gated to SEP-B-C-D-(PP) to form the full-length protein
construct SEP-A-(PP)-B-C-D-(PP). Recovered yields
ranged from 40%–70% for each individual ligation step,
while deprotection and modification reactions gave re-
covered individual step yields ranging from 75%–90%.
This provided for efficient assembly of sufficient mater-
ial (300 g to more than 25 mg based on protein back-
bone concentration) for subsequent biophysical and bi-
ological characterization of each SEP construct.
We also tested an alternative strategy in which a
short linear chain consisting of two precision polymer
repeat units was first attached to segments SEP-A and
SEP-D for the synthesis of SEP-B54 (32−). The objec-
tive of this strategy was the generation of a large batch
of linear polypeptide with the short precision polymer
chain attached. Removal of the precision polymer and
subsequent modification would then allow attachment
of multiple different polymers to the polypeptide, allow-
ing for the generation of polymer diversity in fewer syn-
thetic steps (see Figure S2 in the Supplemental Data
available with this article online). The short precision
polymer chains could be removed efficiently (>90%) in
Chemistry & Biology
374Figure 2. Assembly of SEP Molecules SEP-B51 (8−) and SEP-B50 (0)
Assembly for SEP-B54 (32−) is shown in Figure S2. See main text for details.50% aqueous acetonitrile containing 0.1% TFA in the c
upresence of 1 M aminooxyacetic acid overnight. At-
tachment of the branched polymer of SEP-B51 (32−) f
ywas achieved after a desalting step, but resulted in re-
covered yields of only 10%–20%, presumably due to p
the larger size of the full-length polypeptide chain com-
pared to the individual peptide segments and reduced A
Asolubility of the longer peptide chain.
u
cProtein Folding
The synthetic SEP polypeptides were folded in the s
cpresence of a redox shuffling agent that was added to
control the redox potential of the folding solution and r
dto promote disulfide bond formation and shuffling [24].
The most significant side products of the folding reac- t
stion were the formation of misfolded dimeric and oligo-
meric proteins. Depending on the pI of the target pro- r
itein, oligomeric species and other impurities were
removed by cation exchange or anion exchange purifi- sation. A final size-exclusion chromatography step was
sed to remove residual impurities and to provide for
inal buffer exchange. Overall folding and purification
ields typically ranged from 20%–40% total recovered
rotein (purity >93%) for all analogs.
nalytical Characterization
series of complementary analytical techniques were
sed to unequivocally demonstrate that the SEP mole-
ules were monodisperse, pure, had a defined covalent
tructure, and were correctly folded. All proteins were
haracterized by reversed-phase HPLC to assess pu-
ity, by electrospray ionization mass spectrometry to
etermine precise mass, by isoelectric focusing to de-
ermine the isoelectric point, and by circular dichroism
pectroscopy to assess folding. Figure 3 presents the
eversed-phase HPLC chromatograms, electrospray
onization mass spectra, and circular dichroism (CD)
pectra for each of the four analogs. In the HPLC chro-
Precision Polymer Protein Optimization
375Figure 3. Analytical Characterization of SEP-L30 (0), SEP-B50 (0), SEP-B51 (8−), and SEP-B54 (32−)
Top, reversed-phase HPLC chromatograms of the folded and purified SEP analogs; middle, reconstructed electrospray mass spectra of
folded, purified SEP analogs (see also Table 1); bottom row, circular dichroism spectra of all SEP analogs.matograms, all products exhibited a single peak with a
retention time at w13 min. The shape of the HPLC
peaks indicated satisfactory purity, and the small ob-
served shift in retention times between the analogs
suggests that the nature of the attached precision poly-
mers does not significantly affect the hydrophobicity of
the various SEP analogs. The good correlation of the
theoretically calculated mass with the mass observed
in the electrospray ionization mass spectra of each an-
alog demonstrated correct assembly of the target
structures (see Table 1). A minor satellite band at a
mass of −302 Da, which is observed in all products,
was assigned to a mixed population of species missing
one polymer repeat unit. Thew55 Da mass adduct lad-
ders observed in analog SEP-L30 (0) were most likely
due to the chelation of traces of Fe (the isotope distri-
bution is not resolved at such high masses) by the eth-
ylene oxide-containing polymer that is not disrupted by
the electrospray ionization process. The same adduct
ladders were occasionally observed for the isolated
precision polymer. The mass adduct ladders in the
spectrum of SEP-B50 (0) were not as well resolved, and
therefore assignment is more difficult. The noncovalent
nature of the adducts in both cases was confirmed by
the dependence of the relative intensity of these peaks
on spectrometer orifice potential (data not shown). Fi-
nally, analog SEP-B54 (32−) exhibited a significant ad-duct with a mass of +238. The origin of this adduct
could be traced back to the assembly of the branched
glutamate cluster at the terminus of the linear precision
polymer portions of SEP-B54 (32−), and it thus is only
present in one out of eight branches of the polymer in
each molecule. We were unable to identify the nature
of this adduct. The isoelectric focusing gels exhibited
sharp bands for each analog (data not shown). The ex-
perimentally determined isoelectric points tabulated in
Table 1 were in accord with the predicted isoelectric
points based on the molecular composition. To verify
that the folding and purification procedures and the at-
tachment of the respective polymers, respectively, did
not affect secondary structure formation, CD spectra
were acquired in the far UV region between 200 and
260 nm. Figure 3 shows the CD spectra of each of the
four SEP analogs. The CD spectra exhibit a negative
extremum at 209 nm and a shoulder at around 222 nm,
consistent with protein containing predominantly heli-
cal and disordered loop structures. The CD spectra of
the SEP analogs were thus consistent with the helical
structure of a folded long-chain cytokine, indicating
that secondary structure formation was independent of
the nature of the attached polymer [25].
SEP-B51 (8−) was further characterized by tryptic
mapping to confirm site-specific polymer attachment
and correct disulfide bond formation. Table S1 lists the
Chemistry & Biology
376Table 1. Summary of Physical and Biological Properties of the SEP Constructs
EPO (Multiple
Glycoforms) SEP-L30 (0) SEP-B50 (0) SEP-B51 (8−) SEP-B54 (32−)
Molecular weight (Da) w30 kDa 29,725 ± 15 (29,706) 50,256 ± 15 (50,253) 50,825 ± 15 (50,821) 54,184 ± 15 (54,167)
(theoretical)
Polymer structure branched sugars linear PP branched PP branched PP branched PP
Charge on polymer w−7 to −14 0 0 −8 −32
Total charge at pH = 7 w−2 to −10 +5 +5 −2 −26
PI (IEF) 4.4–5.0 7.9 7.9 5.0 <4
Cell proliferation activity: 1.5 ng/ml ± 0.7 5 ng/ml ± 2.1 10 ng/ml ± 3 1.5 ng/ml ± 0.7 5 ng/ml ± 2.1
ED50 average of
multiple experiments
Posthypoxic mouse 150 mU/ng no activity at tested 32 mU/ng 150 mU/ng no activity at tested
model activity (95% (standard concentratios (24–41 mU/ng) (115–193 mU/ng) concentrations
confidence interval) assigned activity)
Mean residence time 5.9 hr ± 1.2 not detectable at ND 13.0 hr ± 0.8 not detectable at
(MRT) t = 5 mina t = 5 min
a The PK for SEP-L30 was performed with a structurally comparable analog with a net charge of +3.peptide fragments expected after tryptic digest of SEP- r
mB51 (8−) arranged by sequence position. Figure S1
presents an RP-HPLC peptide map of the tryptic di- d
cgest. A total of 17 peaks were designated, and the
peaks were labeled from A to R. The peaks were iden- c
atified by ESI-MS and thus correlated to the expected
peptide fragments as presented in Table S1. Every ex- h
opected peptide fragment was detected with the excep-
tion of two dipeptides (amino acid residues 151, 152, o
Sand 153, 154) and two individual amino acids (amino
acid residues 53 and 140), accounting for >96% (160 f
Bout of 166) of the total protein backbone. Peptide frag-
ments P (amino acid residues 21–38) and Q (amino acid (
residues 117–131) were the only peptide fragments with
a mass detected at >16 kDa by ESI-MS. These two
fragments contained SEP amino acid residues 24 and
126, respectively (as verified by N-terminal sequencing
and ESI-MS), thus confirming site-specific attachment
of the branched precision polymer. Peptide fragments
I (amino acid residues 5–10 disulfide bonded with
amino acid residues 155–162) and P (amino acid resi-
dues 21–38) were expected to contain the postulated
disulfide bonds. Both fragments were isolated from the
HPLC run, lyophilized, and reduced after dissolving into
100 mM phosphate (pH 8.0) and reduction with 100 mM
DTT (dithioerythrol) for 1–2 hr at room temperature. Af-
ter reduction, the peptide fragments were reinjected
onto the HPLC column. HPLC-MS analysis of these re-
duced samples positively identified the expected re-
duced peptide fragments. These results positively
demonstrate the presence of a disulfide bond in SEP-
B51 (8−) between the thiol groups on Cys 7 and Cys
161 as well as Cys 29 and Cys 33, respectively.
Cell Proliferation Activity
All SEP analogs were tested for in vitro cell-proliferation
activity employing the UT/7 Epo cell line that responds F
Sto EPO but not to other related growth factors [26]. Fig-
C
ure 4 shows a representative set of the cell proliferation
Oactivity data for SEP-L30 (0), SEP-B50 (0), SEP-B51
w
(8−), SEP-B54 (32−), and EPO as a function of concen- 
tration. All compounds were found to have cell-prolifer- C
sation acitivity at the concentrations tested as summa-see Table 1). Thus, proteins with significantly greater
igure 4. Growth of UT/7 Epo Cells in the Presence of SEP-L30 (0),
EP-B50 (0), SEP-B51 (8−), SEP-B54 (32−), and EPO at Various
oncentrations
ne representative data set of multiple experiments is shown. Cells
ere grown in multiwell plates at a concentration of 5000 cells/50
l. The plates were incubated at 37°C in the presence of 5% CO2.
ell proliferation was assessed by MTT assay after 5 days. Results
hown are the mean of triplicates of one representative experiment.ized in Table 1 (which presents the averages of
ultiple experiments for each compound), although the
ifferent shapes of the response curves prohibited ac-
urate determination of ED50 values. The presence of
ell-proliferative activity confirmed correct folding of all
nalogs, since misfolded proteins are not expected to
ave significant biological activity. Several trends were
bserved. SEP-B51 (8−) had activity comparable to that
f EPO. In contrast, the cell-proliferation activity of
EP-L30 (0) and SEP-B54 (32−) was reduced by a
actor ofw3, while the cell-proliferation activity of SEP-
50 (0) was reduced by a factor of w7 relative to EPO
Precision Polymer Protein Optimization
377positive charge [SEP-B50 (0)] or with significantly
greater negative charge [SEP-B54 (32−)] had a substan-
tially lower cell-proliferation activity compared to EPO.
In Vivo Activity in the Posthypoxic
Polycythemic Mouse Model
Erythropoietic activity of the SEP analogs was eval-
uated in comparison to EPO in the posthypoxic polycy-
themia assay in mice [27]. Polycythemia was induced
in normal mice by exposure to intermittent hypobaric
hypoxia in a simulated high-altitude chamber for a 3
week period, which stimulated endogenous EPO syn-
thesis and secretion and thus increased red cell pro-
duction. The polycythemic mice were then returned to
sea level conditions, which resulted in an almost com-
plete suppression of red cell production. Injection of
exogenous erythropoiesis agents into these posthyp-
oxic polycythemic mice transiently stimulated erythro-
poiesis. The biological response of the polycythemic
mice to the erythropoiesis agent was quantified by the
percentage of injected Fe59 that was incorporated into
hemoglobin molecules synthesized in red-cell precur-
sors. Measurement of 59Fe incorporation was per-
formed at a single time point 5 days after the injections
of the compounds were determined.
Table 1 and Figure 5 summarize the results from the
posthypoxic polycythemic mouse model. SEP-B51 (8−)
and EPO had similar activity in this assay. In contrast,
SEP-B50 (0) had an activity that was decreased by aFigure 5. Comparative In Vitro Activity, In Vivo Activity (Posthypoxic
Polycythemic Mouse Model), and Mean Residence Time of SEP
Analogs Relative to EPO
The proteins are arranged by decreasing experimental isoelectric
point, and the net charges of each protein at pH 7 is indicated on
the x axis (see main text and Table 1 for experimental methods
and results). The PK for SEP-L30 was performed with a structurally
comparable analog with a net charge of +3. [The analog of SEP-
L30 (0) tested in the PK study had an identical protein backbone
and two singly negative linear precision polymers of the same mass
attached to identical sites. This analog had very similar in vitro ac-
tivity to SEP-L30 (0) but did not show any efficacy in normal rats
after repeat dosing.]factor of five. SEP-B54 (32−) and SEP-L30 (0) did not
have any detectable hematopoietic response at com-
parable doses. These results demonstrate that both the
total mass of the polymer and the overall charge of the
polymer had a significant impact on the in vivo potency
of SEP.
Pharmacokinetics in Rats
Pharmacokinetic studies were consistent with the in
vivo activity studies of the respective analogs. SEP-B54
(32−), SEP-B51 (8−), SEP-B50 (0), and a structural ana-
log of SEP-L30 (0) were dosed intravenously in groups
of three rats at 5 g/kg, and the presence of protein-
polymer conjugate at different time points was deter-
mined by an ELISA assay.
Surprisingly, no protein could be detected even at the
earliest time point (t = 5 min) for SEP-B54 (32−), even
though the presence of the protein in the dosing solu-
tion and compatibility of the syringe and tubing with
the protein formulation were verified. This result ex-
plains the lack of in vivo activity observed for this ana-
log, as the molecule does not survive sufficiently long
in the circulation to exert a significant hematopoietic
effect, possibly due to the action of a scavenger re-
ceptor.
The pharmacokinetic analysis for the most potent an-
alog, SEP-B51 (8−) has already been reported [12]. The
change in plasma concentration of SEP-B51 (8−) with
time in male rats receiving a single intravenous dose
of 5 g/kg could be described by a monoexponential
pharmacokinetic disposition function with a half-life of
9.5 ± 0.7 hr. The clearance was 3.4 ml ± 0.1 /hr/kg, with
mean residence time (MRT) of 13.0 ± 0.8 hr. By compar-
ison, the clearance of EPO was about 7-fold greater
than that of SEP-B51 (8−), and the mean residence time
of EPO was about 3-fold shorter than that of SEP-
B51 (8−).
SEP-B50 (0) was also included in this study, but due
to unfortunate circumstances, no data were obtained.
However, indirect evidence suggests that SEP-B50 (0)
may have comparable lifetimes to SEP-B51 (8−). PK
measurements were performed with an analog of com-
parable backbone that carried two neutral mPEG (poly-
ethylene glycol) molecules in the same positions as in
SEP-B50, and lifetimes comparable but slightly shorter
than SEP-B51 (8−) were observed. This makes it likely
that the lifetime of SEP-B50 is comparable to SEP-B51.
The absence of any in vivo activity for SEP-L30 (0)
suggested that this analog is also rapidly cleared. In-
deed, a close analog of SEP-L30 (0) [the analog of SEP-
L30 (0) tested in the PK study had an identical protein
backbone and two singly negative linear precision poly-
mers of the same mass attached to identical sites; this
analog had very similar in vitro activity to SEP-L30 (0),
but did not show any efficacy in normal rats after repeat
dosing] could not be detected at the earliest time point
of 5 min after injection at both 5 and 25 g/kg, consis-
tent with the lack of activity for SEP-L30 (0).
SEP-B51 (8−) Pharmacokinetics and Efficacy
in Cynomolgus Monkeys
To get a more detailed understanding of the biological
properties of the compound most potent in mice, SEP-
Chemistry & Biology
378B51 (8−), in a more clinically relevant animal model, a a
mdetailed PK and efficacy study in cynomolgus monkeys
was performed (Figure 6). In particular, if receptor-
amediated mechanisms were important in the clearance
mechanism of SEP, as postulated for EPO and other t
Pcytokines [28, 29], a significant dose dependence of the
SEP clearance would be expected. After single intrave- i
snous administration of 2 and 20 g/kg, SEP-B51 (8−)
was cleared from the serum with a slightly shorter mean g
aresidence time and elimination half-life following a sin-
gle dose of 2 g/kg when compared to 20 g/kg. As s
csummarized in Table S2, the MRT was determined to
be 19 and 25.3 hr for the 2 and 20 g/kg dose levels, l
rrespectively. The elimination half-lives were determined
to be 13.7 to 18.5 hr for the 2 and 20 g/kg dose levels, P
mrespectively. The volumes of distribution were compa-
rable for both dose levels within the error of the experi- m
3ments. The slight dose dependence of the SEP-B51
(8−) clearance suggests that a receptor-mediated clear- P
mance mechanism might be contributing to the clear-
sance of SEP-B51 (8−) [28]. In order to see a pharmaco-
slogical response at these dose levels, additional doses
swere administered intravenously on day 5 and three
utimes weekly for 3 weeks thereafter. As presented in
aFigure 6, statistically significant increases in hematocrit
were observed on day 11 and showed the expected
adose-response relationship. Therefore, SEP-B51 (8−)
ashows dose-dependent pharmacokinetic properties
sand stimulates increase in red blood cell volume in a
cdose-dependent manner in primates.
m
b
Discussion y
T
The objective of this study was the systematic explora- p
tion of the effect of charge and hydrodynamic radius c
on the potency of SEP using defined, homogeneous p
conjugates. Toward this goal, four SEP analogs were b
prepared and extensively characterized to ensure homo- i
geneity. All constructs had identical polypeptide back- p
bones and polymer attachment sites, but each analog m
had a distinct net charge and a distinct molecular d
weight depending on the attached polymers. In this way, p
the potency and pharmacokinetic properties of the SEP p
constructs were manipulated by adjusting the polymer t
structure and charge. As a consequence, the SAR rela-
mtionships observed could be conclusively assigned toFigure 6. Pharmacokinetics and In Vivo
Hematopoietic Activity of SEP-B51 (8−) in
Cynomolgus Monkeys at Dose Levels of 0,
2, and 20 g/kg
At left, groups of six animals were dosed in-
travenously on day 1. Blood samples were
collected for evaluation of the drug concen-
tration over time by ELISA. On the right, sub-
sequently animals were dosed three times a
week with the protein concentrations indi-
cated. Blood samples were collected for
evaluation of the effect on hematocrit at the
indicated time points.n individual property, such as, e.g., charge, of the
olecule.
This is in stark contrast to more traditional studies
ttempting to correlate hydrodynamic radius and pro-
ein charge to potency, such as hyperglycosylation and
EGylation [30–32], which have difficulty establish-
ng unambiguous structure-function relationships. In
tudies of hyperglycosylated proteins, such as hyper-
lycosylated recombinant EPO [30], sequence changes
re necessary to introduce additional glycosylation
ites, and both hydrodynamic radius and overall charge
hange as a function of the addition of branched, sialy-
ated sugars. Even though in specific cases, notably in
eductive alkylation at the N terminus, site-directed
EG attachment with charge conservation is possible,
ost PEGylation experiments include random attach-
ent of PEG to charged groups, such as lysines [31,
2]. As a result, variation of the number of attached
EG polymers may alter the overall protein charge and
odify the attachment site distribution for steric rea-
ons. By contrast, the use of chemical ligation to as-
emble the polypeptide chain overcomes the issues of
equence and attachment-site variation, whereas the
se of precision polymers allows for variation of charge
nd size without affecting sample homogeneity.
To obtain polymers having a single covalent structure
nd defined charge, multiple linear and branched poly-
mide polymers were assembled by a combination of
olid-phase organic synthesis [20] and subsequent stoi-
hiometric solution coupling. In particular, branched poly-
ers of up to 16 kDa molecular weight were prepared
y condensation of linear blocks of polyamide-polyeth-
leneoxide polymers onto branching templates [8, 33].
he advantages of stepwise polymer assembly com-
ared to standard solution polymerization [34, 35] in-
lude (1) the ability to control the precise length of each
olymer segment, (2) the ability to introduce defined
ranching sites at any desired position, (3) the ability to
ntroduce positive or negative charges at any desired
osition, and (4) the defined assembly of heteropoly-
ers by direct selection of the monomer unit at each
esired position. The homogeneity of our final protein
roducts is a reflection of the high homogeneity of the
olymer starting materials employed in these syn-
heses.
We also had to develop an approach that would per-
it site-specific attachment of polymers while being
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379fully compatible with a sequential native chemical liga-
tion and cysteine-masking strategy used for polypep-
tide assembly. Incorporation of noncoded residues
bearing either a side-chain ketone or aminooxy group,
respectively, at predetermined positions was accom-
plished during peptide-chain assembly. The polymers
were modified to contain either a single aminooxy or a
single ketone group, respectively, that would only react
with its complement on the peptide segments to form
an oxime bond [7]. Following polymer attachment to
two of the four desired peptide segments, assembly of
all segments was accomplished by a combination of
sequential native chemical ligation, cysteine masking,
and folding steps.
Analytical characterization of the folded proteins
confirmed their identity, correct folding, their site-spe-
cific polymer attachment, and the exceptional homo-
geneity of the polymers. In particular, tryptic mapping
analysis of SEP-B51 (8−) verified the correct covalent
structure of the molecules. After protease digestion,
chromatographic separation, and ESI-MS analysis,
peptide fragments spanning the designed attachment
sites, positions 24 and 126, revealed the exclusive
presence of polymer in this location. This confirms the
utility of oxime formation between the peptide seg-
ments and precision polymers to direct the precision
polymer to the intended site of attachment.
Biological studies on the SEP analogs established a
correlation between several structural features of the
attached polymers with potency and circulation lifetime
of the resulting proteins. One correlation was the im-
pact of molecular weight on circulating half-life. When
tested at similar doses for in vivo hematopoietic activity
in the posthypoxic polycythemic mouse model, the
SEP construct bearing two large (16 kDa) neutral
branched polymers [SEP-B50 (0)] exhibited significant
in vivo activity, while the SEP construct with two much
smaller (5.5 kDa) neutral linear polymers [SEP-L30 (0)]
exhibited no detectable hematopoietic activity. This dif-
ference was probably not because of differences in re-
ceptor interaction, as SEP-B50 (0) showed comparable
in vitro cell proliferation activity relative to SEP-L30 (0)
within the error of the measurement. These observa-
tions suggest that overall protein size does not signifi-
cantly affect receptor activation but that there is a size
threshold for in vivo activity that lies above the size of
SEP-L30 (0) but below the size of SEP-B50 (0).
This threshold is most likely controlled by the renal
clearance rate, which in turn depends on the hydrody-
namic radius of SEP, as has been demonstrated for
other proteins [36]. The hydrodynamic radius of glyco-
sylated EPO is close to the threshold for renal clear-
ance and has been reported as 32 Å (corresponding to
a 65 kDa protein such as bovine serum albumin) [25,
37]. Whereas SEP-B51 (8−) eluted earlier by size-exclu-
sion chromatography than BSA, SEP-L30 (0) eluted
considerably later. This is consistent with the hypothe-
sis that SEP-L30 (0) is smaller than EPO and thus below
the kidney threshold, and that SEP-B51 (8−) is larger
than EPO and above the kidney threshold and is thus
removed by alternative mechanisms such as receptor-
mediated clearance.
Another correlation tested was the impact of the
charge of the attached polymers on overall specific ac-tivity of the SEP constructs both in vitro and in vivo.
Although SEP-B50 (0) exhibited significant activity in
the in vitro cell proliferation and in vivo hypoxic polycy-
themic mouse model assays, these activities were ap-
proximately 7-fold and 5-fold less, respectively, than
that of SEP-B51 (8−). The reduced activity of SEP-B50
(0) was thus overcome by addition of four negative
charges to both polymers in SEP-B51 (8−). This analog
showed activity in the in vitro cell proliferation and
hematopoietic activity in the posthypoxic polycythemic
mouse model that was comparable to EPO. In addition
to specific activity, SEP-B51 (8−) displayed superior
pharmacokinetic properties and duration of action, as
reflected by a 3-fold larger mean residence time, a
7-fold lower clearance, and a substantially higher
increase in hematocrit in a normal rat model using both
TIW and QW dosing for 4 weeks, as previously reported
[12]. Addition of even more negative charge to the poly-
mers in SEP-B54 (32−) led to a marked loss of in vitro
cell proliferation activity relative to SEP-B51 (8−). SEP-
B54 (32−) also failed to show any hematopoietic activity
in the posthypoxic polycythemic mouse model. Consis-
tent with these findings, a pharmacokinetic study for
SEP-B54 (32−) found no detectable material in circula-
tion after only 1 hr. Collectively, these results indicate
that in vivo activity for the SEP analogs decreases after
an apparent maximum in total protein charge and that
the net effect of retained specific activity and longer
circulation lifetime results in a significantly higher po-
tency for SEP-B51 (8−) compared to EPO.
The most potent compound of this series, SEP-B51
(8−), was further assessed for potency and pharmaco-
kinetic properties in the more clinically relevant cyno-
molgus monkey model. SEP-B51 (8−) showed an ex-
tended lifetime compared to literature values reported
for EPO [38] and exhibited dose-dependent clearance
and elimination half-lives, suggesting that receptor-
mediated clearance may play a significant role. Further-
more, after repeated dosing, a significant dose-depen-
dent pharmacological activity was observed. SEP-B51
(8−) has now been evaluated in a human clinical trial
and has shown comparable efficacy in terms of in-
creases in reticulocyte counts comparable with the
most potent commercial hyperglycosylated EPO ana-
log [30].
How could we further increase the potency of SEP?
Our study suggests that the polymer weight of the
larger analogs may be sufficient to avoid renal clear-
ance. There also appears to be a maximum in activity
at a polymer charge that is comparable to or larger than
8 but smaller than 32. The most straightforward ap-
proach for further optimization would therefore be to
systematically explore the charge region between 8
and 32 and to evaluate the effect of charge on overall
potency. In addition, the dose dependence of the phar-
macokinetic properties suggests involvement of recep-
tor-mediated clearance. A second avenue for further
improvement may be to move the polymer-attachment
sites to various locations in proximity to the receptor
binding sites [39], with the goal of differentially increas-
ing the receptor off-rate and thereby reducing the ex-
tent of receptor-mediated endocytosis [40].
In conclusion, we have demonstrated that total
chemical protein synthesis can be combined with the
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380Oattachment of performance-enhancing polymers to gen-
ierate homogeneous conjugates and thus to systemati-
Fcally explore the biological properties of polymer-modi-
b
fied proteins. n
f
tSignificance
(
f
Routine production of protein pharmaceuticals by re- t
combinant means is mostly restricted by the use of d
athe 20 coded amino acids as standard building blocks
and the difficulty of posttranslational modification of
gfolded proteins with function-enhancing pharmaco-
Lphores or polymers. Chemical protein synthesis is
r
not limited by either restriction. It is therefore ideally e
suited to address the known shortcomings of existing c
tprotein therapeutics by providing the ability to sys-
Dtematically and rationally modify the biological prop-
werties of a lead protein via chemical modification. This
Fapproach for the optimization of protein leads is
ageneral and can thus be applied to develop new and L
improve existing protein pharmaceuticals. L
s
rExperimental Procedures
(
tPeptide Synthesis
nThe peptide segments for SEP-B51 (8−) and SEP-B50 (0) were as
cfollows: segment SEP-A (1–32), APPRL ICDSR VLERY LLEAK
wEAEK(N-levulinyl) I TTGCA EH(Dnp)- thioester; segment SEP-B
((33–88), C(Acm)SLNE KIT V PDTKV NFYAW(formyl) KRMEV GQQAV
aEVW(formyl)QG LALLS EAVLR GQALL VKSSQ PW(formyl)-thioes-
cter; segment SEP-C (89–116), C(Acm)PLQL H(Dnp)VDKA VSGLR
aSLTTL LRALG AQK-thioester; segment SEP-D (117–166), CAISP
PDAAK(N-levulinyl) AAPLR TITAD TFRKL FRVYS NFLRG KLKLY d
TGEAC(picolyl) RTGDR-carboxylate. o
The peptides were synthesized on either a thioester-generating a
resin or a –O-CH2-Pam (phenylacetamidomethyl) resin by the in situ a
neutralization protocol for Boc (tertbutoxycarbonyl) chemistry O
stepwise solid-phase peptide synthesis [19]. The peptides were c
deprotected and simultaneously cleaved from the resin support w
using HF/p-cresol according to standard Boc-chemistry pro- T
cedures. The resulting peptides were used in unprotected form, r
with the exception of Cys161(Pic), Cys33(Acm), and Cys89 (Acm), a
which were differentially protected for reasons of synthetic strat- p
egy, and His(Dnp) and Trp(formyl), which were conveniently depro- a
tected during the subsequent ligation reactions and workup steps. B
For analogs SEP-L30 (0) and SEP-B54 (32−), the N-levulinyl group L
was replaced with an N-aminooxyacetyl group. Synthetic peptides m
were purified by reversed-phase HPLC and characterized by ESI- (
MS (electrospray ionization mass spectrometry). Dnp, dinitrophe- p
nyl; Acm, acetamidomethyl; Pic, picolyl group. t
d
bPrecision Length Polymer Synthesis
pThe structures of the precision polymers of all four SEP analogs are
ppresented in Figure 1. The linear precision polymer was assembled
rdirectly on resin. The branched precision polymers were assem-
pbled in solution from a template and a linear precision polymer
tprecursor as described below.
pTemplate Synthesis
tThe template was assembled by solid-phase organic synthesis. For
a typical template synthesis, Fmoc-Dpr(Boc-Aoa)-OH (N-α-Fmoc-
N-β-(N-t.-Boc-amino-oxyacetyl)-L-diaminopropionic acid) was
Ccoupled to deprotected Sieber amide resin (Novabiochem, Switzer-
Oland). After removal of the Fmoc group, succinic anhydride was
Acoupled in the presence of 0.5 M HOBT (1-hydroxybenzotriazole)
mand 10% DIEA (diisopropylethylamine) in DMF (dimethylformam-
mide). The free carboxyl group of the resulting resin-bound succinate
0was activated with 1 M carbonyldiimidazole in DMF. A solution of
w50% (4,7,10)-trioxatridecane-1,13-diamine in 0.5 M HOBT in DMF
was reacted with the resin-bound activated acid. Fmoc-Lys(Fmoc)- fH, activated with N-hydroxysuccinimide and diisopropylcarbodi-
mide, was then coupled to the resin. After Fmoc group removal,
moc-Lys(Fmoc)-OH (HOBT/HBTU/DIEA activated) was coupled to
oth the α-amine and -amine of the first resin-bound lysine. Fi-
ally, the Fmoc groups were removed, which left four amino groups
or reaction with linear precision polymer. After completion of syn-
hesis, the template was cleaved from the resin with 4% v/v TFA
trifluoroacetic acid) in dichloromethane. The cleavage solution was
iltered and the template was dissolved in 50% aqueous acetoni-
rile containing 0.1% TFA. The template was purified after 25-fold
ilution by preparative reversed-phase HPLC using a linear water/
cetonitrile gradient and lyophilized.
The pyruvic-acid-containing template was synthesized analo-
ously on a RINK-linker substituted resin, except that Fmoc-
ys(Mtt) was coupled to the resin initially, and the branching lysine
esidues were added using a Boc-Lys (Boc)-N-hydroxysuccinimide
ster precursor. After coupling of the final lysine of the branching
ore, the Mtt side-chain protecting group was removed by multiple
reatments with 2% TFA in DCM. After neutralization with 10%
IEA in DMF, pyruvic acid was coupled to the resin after activation
ith equimolar amounts of DIC and NHS in DCM for 45 min. The
moc groups were then removed, and the template was cleaved
nd purified as described above.
inear Precision Polymer Precursor Synthesis
inear precision polymer was assembled on Sasrin resin as de-
cribed previously [20]. For terminal modification with pyruvate, py-
uvic acid was activated with equimolar amounts of NHS and DIC
1,3-diisopropylcarbodiimide) and coupled to the linear polymer at
he diamine stage [17]. For terminal modification with a single
egative charge, the polymer assembly was stopped at the suc-
inic acid stage, and the terminal carboxyl group was activated
ith 1 M carbonyldiimidazole in DMF. A 10-fold excess of H-Alanine
OtBu)-HCl was coupled to the resin in the presence of 0.5 M HOBT
nd 10% DIEA in DMF. For terminal modification with four negative
harges, the polymer assembly was stopped at the diamine stage,
nd Fmoc-Lys(Fmoc)-OH was activated with NHS and DIC (1,3-
i-isopropylcarbodiimide) and coupled to the resin. After removal
f the Fmoc groups, succinic anhydride was added to the resin,
nd the free carboxyl group of the resin-bound succinic acids was
ctivated with 0.5 M CDI in DMF. A 10-fold excess of H-Glu(OtBu)-
tBu was coupled in the presence of HOBT and 10% DIEA. After
ompletion of the synthesis, the linear precision polymer precursor
as cleaved from the resin with 4% v/v TFA in dichloromethane.
he cleavage solution was filtered, the filtrate was dried by evapo-
ation under vacuum, and the dried polymer was dissolved in 50%
queous acetonitrile. Subsequently, the linear precision polymer
recursor was purified by preparative reversed-phase HPLC using
linear water/acetonitrile gradient.
ranched Polymer Assembly
inear precision polymer precursor was dissolved in anhydrous di-
ethylsulfoxide, activated with an equimolar amount of HATU [O-
7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium-hexafluoro
hosphate] and DIEA, and immediately mixed with the branched
emplate (containing four free amino groups) dissolved in anhy-
rous dimethylsulfoxide at room temperature. The protected,
ranched precision polymer was purified by preparative reversed-
hase HPLC on a linear water/acetonitrile gradient. The lyophilized,
rotected branched precision polymer was dissolved in TFA at
oom temperature to remove the tert-butyl and Boc groups as ap-
licable. After TFA removal by evaporation under vacuum and addi-
ion of 20% aqueous acetonitrile, the target precision polymer was
urified by preparative reversed-phase HPLC with a water/acetoni-
rile step gradient and lyophilized.
hemical Protein Synthesis
xime-Forming Ligations
branched or linear precision polymer and one of the peptide seg-
ents SEP-D and SEP-A, respectively, were jointly dissolved at a
olar ratio of 1:1.2 to 1.5 in 50% aqueous acetonitrile containing
.1% TFA at a peptide concentration of 10 mg/ml, and the solution
as lyophilized. The polymer-modified polypeptide was separated
rom unmodified polypeptide and unreacted polymer by prepara-
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381tive RP-HPLC with a linear water/acetonitrile gradient. Fractions
containing the desired product SEP-D-(PP) and SEP-A-(PP),
respectively, were identified by ESI-MS and/or analytical RP-HPLC,
pooled, and lyophilized.
Ligation 1
Segment SEP-D-(PP) was dissolved in neat trifluoroethanol (TFE)
and mixed at a molar ratio of 1:1.2 to 1.5 with Acm-protected SEP-
C-α-thioester previously dissolved in 6 M guanidine hydrochloride
(GnHCl), 300 mM phosphate (pH 7.9). The clear solution was ad-
justed to a final SEP-D-(PP) peptide concentration of 2 mM and to
an organic solvent content of 30% TFE. Thiophenol was added to
a final concentration of 1% v/v, and the solution was stirred over-
night at room temperature. The ligation mixture was then diluted
with 1 volume of 2-mercaptoethanol, 1 volume of TFE, and 3 vol-
umes of 6 M GnHCl, 300 mM phosphate (pH 7.9) to remove residual
His(Dnp) protecting groups. The product was purified by prepara-
tive RP-HPLC using a linear water/acetonitrile gradient. The Acm
protecting group of the product SEP-C-D-(PP) was removed by
means of a 3-fold molar excess (relative to the total Acm group
concentration) of Hg(acetate)2 for 30 min at room temperature, and
the reaction was quenched by addition of β-mercaptoethanol. The
reaction product was purified by preparative RP-HPLC using a
water/acetonitrile step gradient to yield SEP-C-D-(PP).
Ligation 2
Segment SEP-C-D-(PP) was dissolved in trifluoroethanol (TFE) and
mixed at a molar ratio of 1:1.3 to 1.5 with Acm-protected segment
SEP-B-α-thioester that had been previously dissolved in 6 M
GnHCl, 300 mM phosphate (pH 7.9). The clear solution was ad-
justed to a final SEP-C-D-(PP) peptide concentration of 1 mM and
to an organic solvent content of 30% TFE. Thiophenol was added
to a final concentration of 1% v/v, and the solution was stirred
overnight at room temperature. A solution consisting of 1 volume
of 2-mercaptoethanol, 1 volume of TFE, 3 volumes of 6 M GnHCl,
100 mM acetate (pH 7.9), and 1 volume of piperidine was added to
the ligation solution to remove residual His(Dnp) and Trp(formyl)
protecting groups. The deprotected product was purified by pre-
parative RP-HPLC using a linear water/acetonitrile gradient to yield
Acm-protected SEP-B-C-D-(PP).
Carboxymethylation and Deprotection
Acm-protected SEP-B-C-D-(PP) was dissolved in TFE at 1 mM
concentration and diluted with 10 volumes of 6 M GnHCl, 300 mM
phosphate (pH 7.9). A 25-fold excess of bromoacetic acid (relative
to free thiol groups) dissolved in methanol was added, and the so-
lution was allowed to react for 1 hr. The product was purified by
preparative RP-HPLC column with a step gradient to give Acm-
protected SEP-B-C-D-(PP) carboxymethylated at residues Cys89
and Cys117. For picolyl protecting group removal, zinc dust was
activated by stirring in 2 M HCl for 30 min. Acm-protected, carboxy-
methylated SEP-B-C-D-(PP) was dissolved in neat TFE at about 30
mg/ml. The solution was diluted with 4 volumes of 6 M GnHCl, 50
mM glycine (pH 2.2), containing 35 mg/ml L-methionine, 35 mg/ml
sodium dodecanoylsarcosine, and 10% TFE. The solution was then
added to the activated zinc powder. After completion of the depro-
tection reaction, the supernatant was removed and the remaining
zinc powder was washed three times to remove adsorbed product.
Sodium dodecanoylsarcosine detergent was removed from the so-
lution of product by treatment with Biobeads SM 2 adsorbent. The
product was purified by preparative RP-HPLC using a step gradi-
ent. The Acm protecting group removal was then performed with
Hg(OAc)2 as described above to yield carboxymethylated SEP-
B-C-D-(PP).
Ligation 3
Carboxymethylated SEP-B-C-D-(PP) was dissolved in a TFE/6 M
GnHCl, 300 mM phosphate (pH 7.9) mixture (1:2) and then com-
bined at a molar ratio of 1:1.2 to 1.5 with segment SEP-A-(PP)-α-
thioester previously dissolved in 6 M GnHCl, 300 mM phosphate
(pH 7.5). The clear solution was adjusted to a final SEP-B-C-D-(PP)
peptide concentration of 1 mM and to an organic solvent content
of 30% TFE. Thiophenol was added to a final concentration of 1%
v/v, and the solution was stirred overnight. The product was puri-
fied by preparative RP-HPLC. HPLC fractions were analyzed by
mass spectrometry and analytical RP-HPLC, and those containingthe unfolded full-length polypeptide product were combined for the
following folding steps.
All analog molecules were prepared following a comparable pro-
cedure, except for SEP-B54 (32−).
Synthesis of SEP-B54 (32−)
SEP-B54 (32−) was assembled employing a strategy that relied on
the protection of the N-aminooxyacetylgroup with a two-repeat
unit precision polymer. After peptide assembly as described above,
a small linear precision polymer [two repeat units of Succinic acid-
(4,7,10)-trioxa-1,13 tridecanediamine) capped with levulinic acid]
was linked to the polymer attachment site using the same condi-
tions as described above for the oximation with larger precision
polymers. Subsequently, the full-length peptide chain was assem-
bled as described above to arrive at the full-length peptide chain.
Taking advantage of the lability of the oxime bond to strong nu-
cleophiles at low pH, the short linear precision polymer was dis-
placed in a solution of 1 M aminooxyacetic acid in 6 M guanidinum
chloride (pH 2), resulting in the full-length polypeptide chain now
carrying two free aminooxy groups. The product was desalted by
preparative RP-HPLC in order to remove aminooxyacetic acid
using a step gradient. HPLC fractions were analyzed by mass
spectrometry and analytical RP-HPLC, and those containing the
deprotected full-length polypeptide product were combined for the
subsequent oximation step, resulting in a solution of the full-length
peptide of w1 mg/ml in w50% aqueous acetonitrile containing
0.1% TFA. For oximation, a 10-fold molar excess of the 16-fold
negatively charged branched precision polymer of SEP-B54 (32−)
was added to this solution. The product was purified by preparative
RP-HPLC. HPLC fractions were analyzed by mass spectrometry
and analytical RP-HPLC, and those containing the unfolded full-
length polypeptide product were combined for the folding steps.
Folding and Purification
The full-length, polymer-modified polypeptide product was folded
using a stepwise dialysis method. Initially, the polypeptide was di-
luted to a protein concentration of 0.1 mg/ml into HPLC buffer (40%
isopropanol and 20% acetonitrile in 0.1% aqueous TFA) containing
6 M GnHCl and 100 mM Tris-HCl (pH 8.5). This solution was then
dialyzed overnight into the first folding buffer (3M GnHCl, 100 mM
Tris-HCl [pH 8.5]) in the presence of a redox couple (8 mM glutathi-
one [reduced], 1 mM glutathione [oxidized]). The buffer was then
exchanged to the second folding buffer (1 M GnHCl, 100 mM Tris-
HCl [pH 8.0]) by dialysis for 8 hr. Finally, the buffer was exchanged
to 10 mM HPO4− (counterion sodium) or 10 mM Tris-HCl (pH 7.0),
overnight, respectively. The folded protein solution was then con-
centrated to 2–2.5 mg/ml by stirred-cell or centrifugal ultrafiltration
devices. Depending on the net charge of the desired product, puri-
fication was achieved on either Q-Sepharose anion exchange chro-
matography (initial buffer: 10 mM Tris-HCl) or Resource-S cation
exchange chromatography (initial buffer: 10 mM HPO4− [counterion
sodium]) using gradients of 0–500 mM NaCl for elution. If desired,
the concentrated protein solution was further purified by size-
exclusion chromatography on a Sephacryl S-300 column using 10
mM Tris-HCl (pH 7.5), 100 mM NaCl as the running buffer.
CD Spectroscopy
Purified SEP analogs were diluted to a final concentration of w50
g/ml in 1 mM Tris-HCl (pH 7.0), 20 mM NaCl. Protein concentra-
tions were determined using an extinction coefficient of 1.61 OD/
(ml/mg) cm. Spectra were acquired with a JASCO-J700 CD spec-
trometer at 20°C between 200 and 260 nm in 0.4 nm increments
(bandwidth, 1 nm; dwell time, 2s; averaged over ten acquisitions).
HPLC Analysis and Tryptic Peptide Mapping Characterization
Analytical reversed-phase HPLC of folded SEP analogs was per-
formed with a linear gradient of 25%–85% buffer B (60% isopropa-
nol, 30% acetonitrile and 10% water containing 0.08% TFA) versus
0.1% aqueous TFA over 24 min on a Vydac C-4 analytical column.
Products were detected at 214 nm. The SEP-B51 (8−) sample solu-
tion was digested with trypsin protease in a substrate:enzyme ratio
of 50:1 (w:w) at 37°C. After digestion, the resulting peptide frag-
ments were separated by RP-HPLC. Analytical reversed-phase
HPLC was performed on aliquots with a linear gradient of 0%–45%
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382buffer C (acetonitrile containing 0.08% TFA) versus 0.1% aqueous m
dTFA over 60 min on a Vydac C-4 analytical column. Peaks were
collected and identified by ESI-MS as well as N-terminal sequenc-
ing analysis.
S
S
Activity Assay in Human UT/7 EPO Cells a
In vitro cell proliferation activities of the analogs and of EPO as a
reference standard were determined in a factor-dependent cell-line
proliferation assay. Stock solutions of the proteins in Iscove’s modi- A
fied Dulbecco’s medium, 10% FBS (fetal bovine serum), glutamine,
and Penstrep, and serial 2× dilutions of this stock solution were W
added to multiwell plates to which human UT/7 EPO cells [26] at B
a concentration of 5000 cells/50 l were added. The plates were v
incubated at 37°C in the presence of 5% CO2 and monitored daily (
for growth. After 4 days, 20 l of 2.5 mg/ml methylthiazoletetra- Y
zolium in PBS was added, and the plates were incubated for 4 hr. S
150 l isopropanol was added and the absorbance of each well t
was read at 562 nm. The activity was corrected for background e
activity and normalized for the final plateau absorbance. Concen- p
trations were given as the concentration of the polypeptide chain.
R
RPosthypoxic Polycythemic Mouse Model
AGroups of 10 mice each (vehicle control, EPO at four dose levels,
Pand SEP analogs at four dose levels) were exposed 18 hr per day
to atmospheric air maintained at 506.5 mb in a simulated high-
Raltitude chamber for 20 days (days 1–20). Iron dextran (2 mg) was
injected before exposure to assure adequate iron stores and permit
the development of polycythemia. Four days after the end of this
pretreatment (day 24), the vehicle or dilutions of EPO or the SEP
analogs were injected intravenously (IV) in a 200 µL volume. Two
days later (day 26), each mouse was injected intraperitoneally (i.p.)
with 0.2 µCi of 59Fe. Three days after radioiron injection, mice were
bled and hematocrit was determined by the microhematocrit
method. The amount of 59Fe (cpm-BG) present in 0.5 ml of blood
was then measured in a web-type scintillation counter. The 72 hour-
RBC59Fe uptake for each animal was calculated and represents the
response. Data from mice with hematocrits below 52% at the time
of euthanasia were discarded. Data from each animal and from dif-
ferent groups were statistically analyzed through linear regression
analysis. The statistical model used was the “parallel-line” model,
in which the relationship between the logarithm of the dose and
the response can be represented by a straight line over the range
of doses used.
Pharmacokinetics in Rats
A single dose of SEP analogs or EPO was administered intrave-
nously to groups of six male rats on day 1. Blood samples were
collected predose and at 5, 30, and 60 min and 2, 4, 8, 24, 48, 72,
96, 120, 144, and 168 hr post-dose. The Quantikine ELISA (R&D
System) for EPO was used to assay plasma concentration of SEP 1
and EPO according to the manufacturer’s instructions. Serum sam-
ples were analyzed at three dilutions in duplicate. A least-squares
analysis of the logarithms of the concentrations was performed, 1
and the pharmacokinetic parameters were extracted.
1
PK/PD Study in Cynomolgus Monkeys
Groups of six animals were dosed intravenously on days 1, 5, 7, 9,
11, 13, 16, 18, 20, 23, 25, and 27 with SEP-B51 (8−) at protein back-
bone concentrations of 0, 2, and 20 g/kg. After the first injection,
samples of blood for ELISA analyses were collected via venipunc- 1
ture into tubes without anticoagulant at 5, 30, and 60 min and at 2,
4, 8, 24, 48, 72, and 96 hr post dosing. The Quantikine ELISA (R&D
System) for EPO was used to assay plasma concentration of SEP
and EPO according to the manufacturer’s instructions. Serum sam-
ples were analyzed at three dilutions in duplicate. A least-squares 1
analysis of the logarithms of the concentrations was performed,
and the pharmacokinetic parameters were extracted. For efficacy
determination, samples were collected on days 1, 2, 3, 5, 11, 16,
18, 25, 27, 28, 29, and 30, and the hematocrit was determined byeasurement of the packed cell volume for each time point imme-
iately after blood collection.
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